Linking Migraine to Gut Dysbiosis and Chronic Non-Communicable Diseases

Association between dietary index for gut microbiota and self-reported severe headache or migraine in U.S. adults: a cross-sectional study from NHANES

Background

The diet-microbiota-gut-brain axis is an emerging frontier in brain health, with microbiota-targeted dietary interventions offering potential benefits. This study aimed to explore the association between the recently introduced dietary index for gut microbiota (DI-GM) and self-reported severe headache or migraine in U.S. adults.

Methods

This cross-sectional study analyzed the National Health and Nutrition Examination Survey (NHANES) data from 1999 to 2004. Severe headache or migraine was determined based on participants' responses to the question: "Have you had a severe headache or migraine in the past 3 months?" The DI-GM was calculated from dietary recall data. Multivariable logistic regression models were performed to evaluate the odds ratio (OR) and 95% confidence interval (95% CI) for the association between DI-GM and severe headache or migraine. Secondary analyses included restricted cubic splines (RCS) and subgroup analyses.

Results

After adjustments, a higher DI-GM score and BGMS were associated with a lower prevalence of severe headache or migraine (DI-GM: OR = 0.95, 95% CI = 0.91-0.99, p = 0.011; BGMS: OR = 0.90, 95% CI = 0.85-0.96, p = 0.003). RCS showed a linear relationship between DI-GM and severe headache or migraine. In two-piecewise regression models, the adjusted OR for developing a severe headache or migraine was 0.90 (95% CI = 0.85-0.97, p = 0.005) in participants with a DI-GM score ≥ 4, whereas no association was observed in those with a DI-GM score < 4.

Conclusion

The DI-GM was negatively associated with the prevalence of self-reported severe headache or migraine in U.S. adults, particularly when scores exceeded 4.

Changes in the metabolome, lipidomein, and gut microbiota in Behçet's disease

Backgrounds

There is growing evidence that autoimmune illnesses are associated with the metabolome and microbiota. Because Behçet's disease (BD) is not often diagnosed as a systemic disorder, the aim of this research was to investigate changes in gut flora and metabolites in BD patients.

Methods

We used 16S rRNA gut microbiota gene sequencing and UPLC-QTOF-MS analysis to gather stool and serum samples from 12 age-matched healthy controls and 17 BD patients. The correlation between changes in gut microbiota and metabolites was then further analyzed.

Results

In contrast to healthy controls, our investigation revealed significant changes in the makeup of gut flora in BD patients. In particular, we observed that in the BD group, there was a large drop in clostridia but a noticeable rise in γ-proteobacteria and betaproteobacteria. The serum metabolomics profiles of BD patients and healthy controls may be reliably differentiated using unsupervised principal component analysis (PCA). Several metabolites, including L-phenylalaine, tricarballylic acid, beta-leucine, ketoleucine, ascorbic acid, l-glutamic acid, l-malic acid, d-glucopyranuronic acid, and methyl acetoacetate, were found to have differential expression between BD patients and healthy controls. All of these metabolites were significantly lower in the BD group. Furthermore, we discovered strong associations between the detected metabolites such as tricarballylic acid, L-malic acid, D-glucopyranuronic acid with certain microbial families, such Prevotellaceae and Alcaligenaceae.

Conclusion

Patients with BD were found to have significant changes in the makeup of their gut flora and metabolites.

Pediatric migraine is characterized by traits of ecological and metabolic dysbiosis and inflammation

BACKGROUND

Recently, there has been increasing interest in the possible role of the gut microbiota (GM) in the onset of migraine. Our aim was to verify whether bacterial populations associated with intestinal dysbiosis are found in pediatric patients with migraine. We looked for which metabolic pathways, these bacteria were involved and whether they might be associated with gut inflammation and increased intestinal permeability.

METHODS

Patients aged between 6 and 17 years were recruited. The GM profiling was performed by the 16S rRNA metataxonomics of faecal samples from 98 patients with migraine and 98 healthy subjects. Alpha and beta diversity analyses and multivariate and univariate analyses were applied to compare the gut microbiota profiles between the two group. To predict functional metabolic pathways, we used phylogenetic analysis of communities. The level of indican in urine was analyzed to investigate the presence of metabolic dysbiosis. To assess gut inflammation, increased intestinal permeability and the mucosal immune activation, we measured the plasmatic levels of lipopolysaccharide, occludin and IgA, respectively.

RESULTS

The α-diversity analysis revealed a significant increase of bacterial richness in the migraine group. The β-diversity analysis showed significant differences between the two groups indicating gut dysbiosis in patients with migraine. Thirty-seven metabolic pathways were increased in the migraine group, which includes changes in tryptophan and phenylalanine metabolism. The presence of metabolic dysbiosis was confirmed by the increased level of indican in urine. Increased levels of plasmatic occludin and IgA indicated the presence of intestinal permeability and mucosal immune activation. The plasmatic LPS levels showed a low intestinal inflammation in patients with migraine.

CONCLUSIONS

Pediatric patients with migraine present GM profiles different from healthy subjects, associated with metabolic pathways important in migraine.

Benefit of Dietary Supplementation of Nutraceuticals as an Integrative Approach for Management of Migraine: Evidence From Preclinical and Clinical Studies

PURPOSE OF REVIEW

To provide information from preclinical and clinical studies on the biological activity and health benefits of dietary inclusion of nutraceuticals as a safe, effective, non-pharmacological approach for the treatment of migraine.

RECENT FINDINGS

There is emerging evidence of the therapeutic benefit of nutraceuticals to inhibit oxidative stress, suppress inflammation, and prevent changes in the normal gut microbiome, which are implicated in migraine pathology. Nutraceuticals can be enriched in polyphenols, which act as molecular scavengers to reduce the harmful effects of reactive oxygen species and phytosterols that suppress inflammation. Nutraceuticals also function to inhibit dysbiosis and to maintain the commensal intestinal bacteria that produce anti-inflammatory molecules including short-chain fatty acids that can act systemically to maintain a healthy nervous system. Dietary inclusion of nutraceuticals that exhibit antioxidant, anti-inflammatory, and anti-nociceptive properties and maintain the gut microbiota provides a complementary and integrative therapeutic strategy for migraine.

Health equity, care access and quality in headache - part 1

Current definitions of migraine that are based mainly on clinical characteristics do not account for other patient's features such as those related to an impaired quality of life, due to loss of social life and productivity, and the differences related to the geographical distribution of the disease and cultural misconceptions which tend to underestimate migraine as a psychosocial rather than neurobiological disorder.Global differences definition, care access, and health equity for headache disorders, especially migraine are reported in this paper from a collaborative group of the editorial board members of the Journal of Headache and Pain. Other components that affect patients with migraine, in addition to the impact promoted by the migraine symptoms such as stigma and social determinants, are also reported.